Download Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.
Austria has once again come a little closer to its goal of achieving the highest research and development rate (R&D rate) in the EU. Two thirds of R&D investments are made by industry, of which around 16% are made by foreign companies. Two current examples of investments in Austria from the life sciences sector are Novartis and Ligand Pharmaceuticals.
Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
The subject of impact measurement is of crucial importance for cluster organizations as they continuously aim to enhance their support to their ecosystems with ever more innovative and efficient services. Therefore, the INNAXE’s consortium has recently developed a “Toolbox for Cluster Organisations” allowing them to easily benchmark their regions and monitor the impact of their activities towards their stakeholders.
In the rapidly evolving healthcare landscape, the concept of 4P Medicine—Prevention, Prediction, Precision, and Participation—marks a transformative shift towards personalized healthcare. This approach, refined over the last 15 years, aims to revolutionize how we understand, prevent, and treat diseases by focusing on each patient’s unique needs. The recent whitepaper by Worldwide Clinical Trials highlights the profound impact of 4P Medicine on clinical development and patient care.
440 participants discussed the defossilisation of the chemical and materials industry through biomass, CO2 and recycling. The audience voted for the “Renewable Material of the Year 2024”: Acetic acid from CO2 by Danish start-up Again wins 1st price.
Mk2 Biotechnologies GmbH was founded in 2020 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
Over the past few years, the Frankfurt Institute of Clinical Cancer Research (IKF) has successfully conducted over 90 clinical studies. Each year, it enrolls approximately 1,500 patients in these trials. European Biotechnology spoke with the founder and director Prof. Dr med. Salah-Eddin Al-Batran.
Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research.
APEIRON/invIOs
Sino Biological
BioRN